<i>IL-1β</i>
            Gene Polymorphism and Serum Levels in a Tunisian Population With Acute Heart Failure

Trabelsi, Imen; Messous, Salma; Chehaibi, Khouloud; Habib, G; Beltaïef, Kaouthar; Nejia, Tounsi; Gannoun, Imen; Boubaker, Hamdi; Boukef, Riadh; Bouida, Wahid; Naceur, Slimane Mohamed

doi:10.2217/bmm-2017-0179

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For IL-10 (-592 C>A), comparison of genotype frequencies between CRC cases and healthy controls showed that carriers of the C/A genotype were negatively associated with CRC occurrence. This was consistent with the meta-analysis conducted in a Chinese population where it was stated that this variant was associated with a significantly reduced CRC risk [31]; similar findings were reported in an ethnic Kashmiri population where the carriers of the minor allele A were associated with a reduced CRC risk [40]. Conversely, two meta-analyses found no correlation [24,41].…”

Section: Discussionsupporting

confidence: 89%

Interleukin-1β, interleukin-6 and interleukin-10 polymorphisms in Tunisian patients with colorectal cancer and liver metastasis

Hazgui

Weslati

Ounissi

et al. 2022

Arch biol sci (Beogr)

View full text Add to dashboard Cite

The balance between pro- and anti-inflammatory cytokine expression is essential for an efficient immune response and for the regulation of cancer development and progression. This study analyzed the expression and genetic variation in IL-1?, IL-6 and IL-10 genes and the possible associations with colorectal cancer (CRC) and colorectal liver metastases (CRLM).We examined IL-1?, IL-6 and IL-10 mRNA expression and three gene variants: IL-1? (rs1143627), IL-10 (rs1800872) and IL-6 (rs1800795), in 198 CRC, 65 CRLM patients and 230 controls. Carriers of the C/T genotype of IL-1? (rs1143627) have an increased risk of developing CRC and CRLM. T/T genotype carriers have a higher risk of CRLM incidence. For IL-10 (rs1800872), patients harboring the C/A genotype have a lower risk of CRC and CRLM occurrence. For IL-6 (rs1800795), the C/C genotype heightens the risk of CRLM development. Overall survival analysis showed that carriers of the C/T genotype of IL-1? (rs1143627) have a worse overall survival in CRC patients. It can be concluded that interleukin genetic variants can be used as biomarkers to detect and predict clinical outcomes and prognostic factors for CRC and CRLM.

show abstract

Section: Discussionsupporting

confidence: 89%

Interleukin-1β, interleukin-6 and interleukin-10 polymorphisms in Tunisian patients with colorectal cancer and liver metastasis

Hazgui

Weslati

Ounissi

et al. 2022

Arch biol sci (Beogr)

View full text Add to dashboard Cite

show abstract

“…Just three studies have measured IL-1β along with many other cytokines, and all found that IL-1β levels are elevated in patients with chronic HF compared with controls (8,9,18). In another study, L-1β was significantly higher in patients with ADHF compared with non-HF and control groups (19).…”

Section: Discussionmentioning

confidence: 99%

The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure

Pascual-Figal

Bayés‐Genís

Asensio-López

et al. 2019

Journal of the American College of Cardiology

View full text Add to dashboard Cite

“…High-mobility group box protein 1 (HMGB1) and pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the cortex and hippocampus of CCH mice induced by bilateral carotid artery stenosis (BCAS) have been reported to significantly increase ( 60 ). A clinical study found that the concentration of IL-1β in the serum of HF patients was higher than that of the non-HF and control groups ( 61 ). IL-1β, a pro-inflammatory cytokine, is an important factor driving inflammatory responses in the central nervous system ( 62 , 63 ).…”

Section: Potential Mechanisms Of Cardiogenic Dementiamentioning

confidence: 99%

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Liu,

Xiao,

Liang

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Diagnosis and treatment of patients with cardiovascular and neurologic diseases primarily focus on the heart and brain, respectively. An increasing number of preclinical and clinical studies have confirmed a causal relationship between heart and brain diseases. Cardiogenic dementia is a cognitive impairment caused by heart dysfunction and has received increasing research attention. The prevention and treatment of cardiogenic dementia are essential to improve the quality of life, particularly in the elderly and aging population. This study describes the changes in cognitive function associated with coronary artery disease, myocardial infarction, heart failure, atrial fibrillation and heart valve disease. An updated understanding of the two known pathogenic mechanisms of cardiogenic dementia is presented and discussed. One is a cascade of events caused by cerebral hypoperfusion due to long-term reduction of cardiac output after heart disease, and the other is cognitive impairment regardless of the changes in cerebral blood flow after cardiac injury. Furthermore, potential medications for the prevention and treatment of cardiogenic dementia are reviewed, with particular attention to multicomponent herbal medicines.

show abstract

IL-1β Gene Polymorphism and Serum Levels in a Tunisian Population With Acute Heart Failure

Abstract: IL-1β levels may be useful for the evaluation of diagnosis in acutely decompensated HF.

Cited by 5 publications

References 30 publications

Interleukin-1β, interleukin-6 and interleukin-10 polymorphisms in Tunisian patients with colorectal cancer and liver metastasis

Interleukin-1β, interleukin-6 and interleukin-10 polymorphisms in Tunisian patients with colorectal cancer and liver metastasis

The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure

Heart–brain interaction in cardiogenic dementia: pathophysiology and therapeutic potential

Contact Info

Product

Resources

About